arylsulfatase family member IGenealiases: ASI · SPG66
Q-omics provides the consensus-scored ARSI profile across patient tissues and cancer cell-line models. ARSI expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ARSI is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, ARSI RNA expression shows 18,853 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight MESO, HNSC, and PDAC as cancer lineages where ARSI shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARSI — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARSI survival associations across molecular data types. ARSI RNA expression shows survival associations in the most cancer types (29), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARSI RNA expression–survival associations across cancer types. High ARSI expression shows unfavorable associations in MESO, KIRC, BLCA, HNSC, LGG and KIRP. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ARSI RNA expression.
This table summarizes ARSI tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ARSI. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARSI shows lower tumor expression in KIRC and UCEC and higher tumor expression in HNSC, THCA, COAD and BRCA. The HNSC box plot shows higher ARSI RNA expression in tumor versus normal tissue (log2 FC = +2.037, t-test p < 0.001).
This table shows molecular features associated with ARSI in patient tissues and cancer cell lines. In patient samples, ARSI shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, ARSI RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BREAST.
